



CONTACT

Bill Edelman
President and Chief Executive Officer
TYRX, Inc.
732.246.8676
william@tyrx.com

TYRX to attend the 13th Annual Heart Failure Society of America Meeting (HFSA), Boston, MA

Monmouth Junction, NJ, (September 14, 2009) -- TYRX, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices announced today that it will be exhibiting its lead product, AIGIS_{Rx}TM Anti-Bacterial Envelope, at the 13th Annual Heart Failure Society of America Meeting (HFSA), in Boston, MA this week.

The Heart Failure Society of America, Inc. (HFSA) brings together heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care.

AIGIS_{Rx} is an anti-bacterial mesh envelope developed to deliver anti-microbial agents that help provide protection against infections associated with implanted pacemakers and cardioverter defibrillators. AIGIS_{Rx} also securely holds a pacemaker (PM) or implantable cardioverter defibrillator (ICD) in order to create a stable environment when implanted in the body.

About TYRX, Inc.

TYRX, Inc., an ISO 9001:2000 and ISO 13485:2003 certified medical device manufacturer, commercializes implantable combination drug/device products, including the AIGIS_{Rx} Anti-Bacterial Envelope. AIGIS_{Rx} contains the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by organisms representing a majority of the infections reported in cardiac rhythm device related endocarditis, including “superbugs” or MRSA. In addition, AIGIS_{Rx} is intended to securely hold a pacemaker or implantable cardioverter defibrillator (ICD) in order to create a stable environment when implanted in the body. Following commercial release in June, 2008, AIGIS_{Rx} has been implanted in over 4,500 patients nationwide. In February, 2008 TYRX raised \$25 million in a venture capital financing led by Clarus Ventures and co-led by Pappas Ventures. TYRX products utilize novel biomaterials, including technology licensed exclusively from Rutgers, The State University of New

Jersey. Additionally, TYRX has exclusively licensed from Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center product patents and associated technologies to address the problem of postsurgical nosocomial infection. TYRX is deploying its capabilities across a broad range of combination implantable medical-pharmaceutical devices. The combination products sector (products incorporating both a drug & a device component) is expected to be the highest growth segment of the medical products industry and TYRX is positioned to be an innovative applications leader in the space.

For more information, please visit www.TYRX.com.

#####